Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: From I-Hub (Nerverending)

The prior 250 million dollars was earned while under a cloud of apparently unsuccessful litigation (Js, Asustek, Sirius) and troubling/worrisome USPTO review of all the patents (like the examiner does not know the proper definition of CPU). If we assume successful defense of the patents at the USPTO and a corresponding success with current infringement litigation, why would one assume we would settle for the same low license fees going forward? While using past numbers in the exercise helps to make Greg's point it, by no means, is a forecast of potential revenue. At least IMHO.

Opty

Share
New Message
Please login to post a reply